Literature DB >> 16429118

A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.

N T Georgopoulos1, L P Steele, M J Thomson, P J Selby, J Southgate, L K Trejdosiewicz.   

Abstract

Membrane-presented CD40 agonists can induce apoptosis in carcinoma, but not normal homologous epithelial cells, whereas soluble agonists are growth inhibitory but not proapoptotic unless protein synthesis is blocked. Here we demonstrate that membrane-presented CD40 ligand (CD154) (mCD40L), but not soluble agonists, triggers cell death in malignant human urothelial cells via a direct mechanism involving rapid upregulation of TNFR-associated factor (TRAF)3 protein, without concomitant upregulation of TRAF3 mRNA, followed by activation of the c-Jun N-terminal kinase (JNK)/activator protein-1 (AP-1) pathway and induction of the caspase-9/caspase-3-associated intrinsic apoptotic machinery. TRAF3 knockdown abrogated JNK/AP-1 activation and prevented CD40-mediated apoptosis, whereas restoration of CD40 expression in CD40-negative carcinoma cells restored apoptotic susceptibility via the TRAF3/AP-1-dependent mechanism. In normal human urothelial cells, mCD40L did not trigger apoptosis, but induced rapid downregulation of TRAF2 and 3, thereby paralleling the situation in B-lymphocytes. Thus, TRAF3 stabilization, JNK activation and caspase-9 induction define a novel pathway of CD40-mediated apoptosis in carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429118     DOI: 10.1038/sj.cdd.4401859

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  28 in total

Review 1.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

2.  The miR-322-TRAF3 circuit mediates the pro-apoptotic effect of high glucose on neural stem cells.

Authors:  Hui Gu; Jingwen Yu; Daoying Dong; Qun Zhou; Jian-Ying Wang; Peixin Yang
Journal:  Toxicol Sci       Date:  2014-12-16       Impact factor: 4.849

3.  An in vitro Co-culture System for the Activation of CD40 by Membrane-presented CD40 Ligand versus Soluble Agonist.

Authors:  Khalidah Ibraheem; Christopher J Dunnill; Myria Ioannou; Albashir Mohamed; Balid Albarbar; Nikolaos T Georgopoulos
Journal:  Bio Protoc       Date:  2018-07-05

4.  The molecular mechanisms of vulpinic acid induced programmed cell death in melanoma.

Authors:  Sevcan Yangın; Demet Cansaran-Duman; Gamze Guney Eskiler; Sümer Aras
Journal:  Mol Biol Rep       Date:  2022-08-12       Impact factor: 2.742

5.  Spatiotemporal pattern of TRAF3 expression after rat spinal cord injury.

Authors:  Ya Wu; Minqian Zheng; Siqing Wang; Changzhi Song; Chuanbin Wang; Yueping Xiao; Lei Xu; Xiaozu Xu
Journal:  J Mol Histol       Date:  2014-05-07       Impact factor: 2.611

6.  CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.

Authors:  Taha Elmetwali; Peter F Searle; Iain McNeish; Lawrence S Young; Daniel H Palmer
Journal:  Mol Cancer       Date:  2010-03-08       Impact factor: 27.401

7.  Differential regulation of growth-promoting signalling pathways by E-cadherin.

Authors:  Nikolaos T Georgopoulos; Lisa A Kirkwood; Dawn C Walker; Jennifer Southgate
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

8.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

Review 9.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

10.  Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.

Authors:  Chi Yan; Nabil Saleh; Jinming Yang; Caroline A Nebhan; Anna E Vilgelm; E Premkumar Reddy; Joseph T Roland; Douglas B Johnson; Sheau-Chiann Chen; Rebecca L Shattuck-Brandt; Gregory D Ayers; Ann Richmond
Journal:  Mol Cancer       Date:  2021-06-06       Impact factor: 41.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.